Issue Date: May 9, 2011
Yale Enters Deals With Biotech Firms
Yale University has signed two collaborations to help advance drug candidates in development. Yale researchers will work with Durham, N.C.-based Icagen and Pfizer to explore investigational compounds targeting sodium channels associated with pain. In an alliance with Switzerland’s Debiopharm, university researchers will help develop inhibitors that target a fundamental inflammatory disease pathway. The partners hope to advance Debiopharm’s Debio 1036 program through preclinical and clinical development.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society